Future newborns with opioid-induced neonatal abstinence syndrome (NAS) could be assessed with the genetic addiction risk severity (GARS) test and potentially treated using precision amino-acid enkephalinase inhibition therapy (KB220) as a frontline modality instead of potent opioids

Authors

Mauro Ceccanti, Sapienza University of Rome
Mark S Gold, Washington University School of Medicine in St. Louis
et al.

Journal

Journal of Personalized Medicine

Publication Date

12-6-2022

Volume

12

Issue

12

First Page

2015

Document Type

Open Access Publication

DOI

10.3390/jpm12122015

Rights and Permissions

Ceccanti, M.; Blum, K.; Bowirrat, A.; Dennen, C.A.; Braverman, E.R.; Baron, D.; Mclaughlin, T.; Giordano, J.; Gupta, A.; Downs, B.W.; Bagchi, D.; Barh, D.; Elman, I.; Thanos, P.K.; Badgaiyan, R.D.; Edwards, D.; Gold, M.S. Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids. J. Pers. Med. 2022, 12, 2015. https://doi.org/10.3390/jpm12122015 This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Recommended Citation

Ceccanti, Mauro; Gold, Mark S; and et al., "Future newborns with opioid-induced neonatal abstinence syndrome (NAS) could be assessed with the genetic addiction risk severity (GARS) test and potentially treated using precision amino-acid enkephalinase inhibition therapy (KB220) as a frontline modality instead of potent opioids." Journal of Personalized Medicine. 12, 12. 2015 (2022).
https://digitalcommons.wustl.edu/oa_4/1063